{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yamamoto JK"],"funding":["NIAID NIH HHS"],"pagination":["14-25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3721975"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy"],"journal":["Current HIV research"],"pubmed_title":["Feline immunodeficiency virus model for designing HIV/AIDS vaccines."],"pmcid":["PMC3721975"],"funding_grant_id":["R01 AI030904","R01 AI065276","R01-AI065276","R01-AI030904"],"pubmed_authors":["Sanou MP","Yamamoto JK","Abbott JR","Coleman JK"],"additional_accession":[]},"is_claimable":false,"name":"Feline immunodeficiency virus model for designing HIV/AIDS vaccines.","description":"Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Jan","modification":"2025-04-26T10:57:30.675Z","creation":"2019-06-05T18:58:15Z"},"accession":"S-EPMC3721975","cross_references":{"pubmed":["20210778"],"doi":["10.2174/157016210790416361"]}}